JANX

Janux Therapeutics Inc

Add to Watchlist

Advanced Chart

24.270

+1.6(7.058%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

24.390

Open

22.670

VWAP

23.89

Vol

555.01K

Mkt Cap

1.46B

Low

22.670

Amount

13.26M

EV/EBITDA(TTM)

Total Shares

51.85M

366.32M

EV/OCF(TTM)

P/S(TTM)

3.04K

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Get winning stock picks in minutes

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

272.73K

-96.93%

Estimates Revision

The market is revising No Change the revenue expectations for Janux Therapeutics, Inc. (JANX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -4.18%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-4.18%

In Past 3 Month

14 Analyst Rating

233.75% Upside

Wall Street analysts forecast JANX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JANX is 81.00 USD with a low forecast of 25.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Buy

1 Hold

0 Sell

Strong Buy

233.75% Upside

Current: 24.270

Low

25.00

Averages

81.00

High

200.00

233.75% Upside

Current: 24.270

Low

25.00

Averages

81.00

High

200.00

Raymond James

Sean McCutcheon

Outperform

initiated

$65

2025-07-11

Reason

Raymond James

Sean McCutcheon

Price Target

$65

2025-07-11

initiated

Outperform

Reason

Raymond James analyst Sean McCutcheon initiated coverage of Janux Therapeutics with an Outperform rating and $65 price target. Janux is clinical-stage company focused on developing masked T-cell engagers for several cancer types, the analyst tells investors in a research note. The firm sees good results to date for JANX007, saying the data offer \"strong proof-of-concept\" for the masking technology employed by Janux.

Scotiabank

Sector Perform

downgrade

$41 -> $36

2025-05-09

Reason

Scotiabank

Price Target

$41 -> $36

2025-05-09

downgrade

Sector Perform

Reason

Scotiabank lowered the firm's price target on Janux Therapeutics to $36 from $41 and keeps a Sector Perform rating on the shares. The firm cut its price target on the stock based on the lower probability of success for its Phase 1 trial of JANX007, which the firm believes is "more appropriate" for a Phase 1 cancer drug with limited patient exposure, the analyst tells investors.

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$70

2025-03-03

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$70

2025-03-03

Reiterates

Strong Buy

Reason

Scotiabank

George Farmer

Hold

Maintains

$62 → $41

2025-02-28

Reason

Scotiabank

George Farmer

Price Target

$62 → $41

2025-02-28

Maintains

Hold

Reason

Cantor Fitzgerald

Josh Schimmer

Buy

Reiterates

$200

2024-12-11

Reason

Cantor Fitzgerald

Josh Schimmer

Price Target

$200

2024-12-11

Reiterates

Buy

Reason

Cantor Fitzgerald raised the firm's price target on Janux Therapeutics to $200 from $100 and keeps an Overweight rating on the shares. Janux Therapeutics reported data for JANX007 for metastatic castration-resistant prostate cancer patients that far exceeded the expectations the firm had captured in a survey a few week ago, and the data may continue to get better as the higher dose cohorts mature, the analyst tells investors in a research note. The firm says there were only minor things to nit-pick and that '007 demonstrated "unprecedented" rates of PSA50, PSA90, overall response rate, and a very well tolerated profile.

Scotiabank

George Farmer

Hold

Maintains

$42 → $62

2024-12-04

Reason

Scotiabank

George Farmer

Price Target

$42 → $62

2024-12-04

Maintains

Hold

Reason

See All Ratings

Get winning stock picks in minutes

Valuation Metrics

The current forward P/E ratio for Janux Therapeutics Inc (JANX.O) is -7.71, compared to its 5-year average forward P/E of -16.11. For a more detailed relative valuation and DCF analysis to assess Janux Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-16.11

Current PE

-7.71

Overvalued PE

-4.77

Undervalued PE

-27.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-8.65

Current EV/EBITDA

-2.02

Overvalued EV/EBITDA

0.19

Undervalued EV/EBITDA

-17.49

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

481.76

Current PS

653.18

Overvalued PS

904.81

Undervalued PS

58.70